JOSÉ LUIS
GONZÁLEZ LARRIBA
Catedrático de universidad
Publicaciones (131) Publicaciones en las que ha participado algún/a investigador/a
2024
-
Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612
2023
-
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513
2022
-
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Annals of Oncology, Vol. 33, Núm. 1, pp. 67-79
-
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
BMC Cancer, Vol. 22, Núm. 1
-
SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 635-645
2021
-
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry
PLoS ONE, Vol. 16, Núm. 6 June
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
-
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
BMC Cancer, Vol. 21, Núm. 1
-
Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
Frontiers in Oncology, Vol. 11
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
-
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
BMC Psychology, Vol. 8, Núm. 1
-
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Lung Cancer, Vol. 147, pp. 83-90
-
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
BJU International, Vol. 126, Núm. 5, pp. 559-567
-
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
Cancer Epidemiology, Vol. 67
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
-
Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)
Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475
2018
-
First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536
-
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
European Respiratory Journal
-
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38
2017
-
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, Núm. 7, pp. 1517-1522